Therapix Biosciences Names Josh Blacher as Chief Financial Officer

Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer

TEL AVIV, Israel, May 3, 2017 /PRNewswire/ — Therapix Biosciences Ltd. (Nasdaq: TRPX) (“Therapix”), a specialty clinical stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that it has appointed Josh Blacher as Chief Financial Officer, effective immediately.

Mr. Blacher joins Therapix with ten years of experience in senior financial and business development related positions at publicly-traded biotechnology and pharmaceutical companies, as well as 14 years in capital markets in the United States. Prior to joining Therapix, Mr. Blacher served as Chief Financial Officer at Galmed Pharmaceuticals (NASDAQ: GLMD). Previously, Mr. Blacher also held senior positions in licensing and investing at Teva Pharmaceuticals, portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in mergers & acquisitions at Lehman Brothers. Mr. Blacher holds an MBA in Finance from Columbia Business School.

“Now that Therapix has completed its U.S. IPO and NASDAQ listing, and initiated additional clinical trials, it is clear that we will need someone of Josh’s caliber to help us develop and bring awareness of our growth strategy to the U.S. capital markets, as well as monetize our assets globally. We’re confident that Josh’s broad-based experience and track record will help us accomplish our objectives,” commented Dr. Elran Haber, Therapix’s Chief Executive Officer and Dr. Ascher Shmulewitz, the Company’s Executive Chairman. Drs. Haber and Shmulewitz continued, “We’re delighted to welcome Josh to the company.”

Therapix has all the makings of a successful specialty pharmaceutical company – compelling technology in areas of high unmet medical needs, strong management and long-term investors, as well as the financial wherewithal to execute its strategy. I am very excited to join Therapix and look forward to helping the company unlock its significant potential.

Josh Blacher TRPXJeremy Blacher, CFO

About Therapix Biosciences

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists, focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma, developing THX-TS01 targeted to the treatment of Tourette’s syndrome; and BrainBright Pharma, developing THX-ULD01 targeted to the high value and under-served market of mild cognitive impairments. More information is available online at

Original press release:

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter